Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,870 total articles
Belite Bio announced an upcoming oral presentation of positive topline results from its Phase 3 DRAGON trial evaluating tinlarebant for Stargardt disease type 1 (STGD1). Tinlarebant showed a significant 35.7% reduction in the growth of atrophic retinal lesions compared to placebo, with a strong safety profile. The therapy targets accumulation of bi…
Kratos Defense & Security Solutions, a Nasdaq-listed technology company serving defense and national security sectors, announced its first quarter 2026 earnings release and conference call scheduled for May 6th. Management will discuss financial results and operational updates, reflecting ongoing activities in defense technology and advanced system…
Humacyte, Inc. announced a virtual key opinion leader event to discuss its Acellular Tissue Engineered Vessel (ATEV) designed for arteriovenous (AV) access in hemodialysis patients. The event will feature leading experts discussing unmet medical needs, current treatment limitations with AV fistulas, and insights on clinical trials including an ongo…
Alpha Compute Corp. provided an update on its NVIDIA Blackwell GPU infrastructure deployments. The company is finalizing testing of its first large-scale GPU cluster (ALPHA-01) consisting of 504 NVIDIA B200 GPUs in Canada, targeting a May 8, 2026 go-live. Despite a delay from March due to supply chain issues, the deployment marks the transition fro…
Microchip Technology announced the opening of a new manufacturing facility in Tuscaloosa, Alabama dedicated to increasing production of its MHM-2020 Active Hydrogen Maser, a highly precise atomic clock used in critical infrastructure and scientific applications. The expansion is aimed at meeting rising global demand and reducing lead times while st…
Apollomics Inc. reported its full year 2025 financial results, highlighting significant progress in its oncology pipeline, particularly with its lead drug vebreltinib. The company is advancing global clinical trials for vebreltinib, a selective c-MET inhibitor approved in China for multiple indications, and plans to submit an IND application in the…
Terra Innovatum highlights the U.S. Nuclear Regulatory Commission's advancement of draft Part 57 rulemaking aimed at enabling efficient, scalable deployment of standardized microreactor systems. The Company’s SOLO™ Micro-Modular Reactor design aligns closely with the new risk-informed, performance-based licensing framework, positioning Terra Innova…
Opus Genetics announced that its leadership team will present encouraging preliminary and preclinical data on its gene therapy programs for inherited retinal diseases at multiple prestigious medical conferences in May 2026. This includes updates on Phase 1b/2a clinical trials for LCA5 and BEST1 gene therapies, highlighting advancements toward durab…
Cerence Inc., a leader in conversational AI for automotive and transportation, announced it will release its fiscal second quarter 2026 financial results on May 7, 2026. The company will host a live conference call and webcast to discuss results, inviting investors and analysts to participate. Cerence noted its strong position in the automotive AI …
FirstCash Holdings, Inc. announced that its wholly-owned subsidiary has commenced a private placement offering of $600 million aggregate principal amount of senior notes due 2034. The proceeds will be primarily used to repay outstanding borrowings under credit facilities, providing additional liquidity to fund future growth. The offering is targete…
OceanFirst Financial Corp. and Flushing Financial Corporation announced that they have received all necessary regulatory and shareholder approvals to complete their proposed merger. The merger is expected to close by June 1, 2026, combining two regional banks serving New Jersey and New York metropolitan markets. Both companies held shareholder meet…
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic neuroplastogen therapies, announced it is evaluating its lead candidate CMND-100 (MEAI) for eligibility for the FDA's Breakthrough Therapy Designation based on positive Phase I/IIa clinical trial results in Alcohol Use Disorder. The designation could accelerate developm…
CADV Ventures S.A., a Poland-based AI software company specializing in AI-assisted IT support services, has entered into a business combination agreement with Miluna Acquisition Corp, a US-based SPAC listed on Nasdaq. Upon closing, the combined company will be named Kukugan Corp and listed on a national securities exchange, with an implied enterpri…
CorMedix Therapeutics reported positive topline results from the Phase III ReSPECT trial evaluating REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in adults undergoing allogeneic hematopoietic stem cell transplantation. The study met its primary endpoint, demonstrating non-inferiority to standard antimicrobial regimens for fu…
Greenlane Holdings, Inc., a Nasdaq-listed digital asset treasury company focused on the Berachain ecosystem, announced that it has regained compliance with Nasdaq's minimum bid price requirement and will continue its listing on the Nasdaq Capital Market under the ticker GNLN. The company's leadership expressed confidence in its Berachain-focused di…
Kustom Entertainment announces its CEO Stanton E. Ross will present at the 16th Annual LD Micro Invitational to outline the company's strategic progress, including its rebrand, business divestitures, expansion of live events, and positive 2026 outlook. The company emphasizes its shift towards a focused live entertainment and ticketing business mode…
NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury, announced the appointment of Keith Vendola as Chief Financial Officer. Vendola brings over 20 years of financial and strategic leadership experience in biopharma and healthcare investment banking. His expertise is expecte…
WW International, Inc., known as Weight Watchers, announced its intention to utilize up to $40 million in cash to prepay and reduce the principal amount of its outstanding term loan. This action includes paying the annual cash sweep amount due in June 2026 and a voluntary prepayment solicitation to reduce debt at a discount. The company reaffirmed …
HCW Biologics announced preclinical data showing its lead T-Cell Engager candidate, HCW11-018b, penetrates the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities. The data, presented at AACR 2026, revealed the drug's mechanism of action based on cis-binding, which enhances efficacy and tolerability. The compan…
Compass Therapeutics announced that tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, combined with paclitaxel, significantly improved median progression-free survival (PFS) and overall response rate (ORR) in patients with unresectable advanced biliary tract cancer in the Phase 2/3 COMPANION-002 study. The treatment reduced risk of progre…
Medicus Pharma's CEO and leadership team met with key U.S. healthcare policymakers on the House Energy & Commerce Committee to promote orphan drug designation and investigational new drug approval for SkinJect®, a novel treatment for Gorlin Syndrome. The company emphasizes SkinJect®'s potential to provide a non-surgical, repeatable therapy for a ra…
BriaCell Therapeutics Corp. announced six clinical data presentations at the 2026 ASCO Annual Meeting, featuring key findings from their Phase 2 and ongoing Phase 3 trials of their novel immunotherapy Bria-IMT combined with CPI in advanced metastatic breast cancer. The presentations include survival data, quality of life assessments, and biomarker …
Keel Infrastructure Corp., a North American digital and energy infrastructure company, will report its first quarter 2026 financial results on May 11, 2026, before the market opens. Management will host a conference call the same day to discuss the results.
Scorpio Tankers Inc. announced a $50 million credit facility commitment from Bank of America to finance two 2015-built LR2 product tankers. The facility has a seven-year maturity and competitive interest terms. This financial move supports Scorpio Tankers' fleet expansion and modernization amid ongoing vessel sales and newbuilding deliveries.
Alterity Therapeutics announced positive regulatory feedback from the FDA following their second Type C Meeting concerning the chemistry, manufacturing, and control aspects of their planned Phase 3 trial for ATH434 in Multiple System Atrophy (MSA). This progress marks a crucial step toward initiating the pivotal trial, with concurrent manufacturing…
